PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • FDA Date: 05/22/2017

    Saxenda (liraglutide) Injection REMS

    Goal of the Saxenda (liraglutide) Injection REMS Program

    The goal of the SAXENDA REMS is to mitigate the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis (including necrotizing pancreatitis) associated with SAXENDA by:

    • Informing healthcare providers about the potential risk of medullary thyroid carcinoma associated with SAXENDA

    • Informing healthcare providers about the risk of acute pancreatitis (including necrotizing pancreatitis) associated with SAXENDA

    REMS Elements

    • Communication Plan